TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6116040

Group type: EXPERIMENTAL
Intervention: Vertical spinning-disc nebuliser
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional compressed air nebuliser
Number of subjects: 8
Study: 30865242

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rested individuals
Number of subjects: 0
Study: 27902833

Group type: EXPERIMENTAL
Intervention: Cangrelor alone
Number of subjects: 12140

Group type: COMPARATOR
Intervention: Clopidogrel-GPI
Number of subjects: 12140
Study: 25804495

Group type: EXPERIMENTAL
Intervention: Amlodipine/perindopril arginine (10/14 mg/d)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (16 mg/d)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Amlodipine (10 mg/d)
Number of subjects: 837
Study: 24053609

Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional robotics-assisted treadmill exercise
Number of subjects: 0
Study: 21389626

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate tablets (5 times more than the effective amount)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study: 19542034

Group type: EXPERIMENTAL
Intervention: Prekindergarten education group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 17942268

Group type: EXPERIMENTAL
Intervention: Video with narrative evidence (patient anecdotes)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Video with statistical evidence
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Video with both narrative and statistical evidence
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (no video)
Number of subjects: 600
Study: 15552163

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral control site
Number of subjects: 20
Study: 11574355

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered 10-15 min before induction of anesthesia
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered at the end of laparoscopy (79 +/- 48 min later than Group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered at the end of anesthesia (93 +/- 52 min later than Group 1)
Number of subjects: 105
Study: 9506639

Group type: EXPERIMENTAL
Intervention: Semi-elemental formula without enzyme replacement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonelemental formula with enzyme replacement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 16
Study: 8573704

Group type: EXPERIMENTAL
Intervention: Sitting position (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supine position (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Half-lying position (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Standing position (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sitting position (Group B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supine position (Group B)
Number of subjects: 82
Study: 2504794

Group type: EXPERIMENTAL
Intervention: Parent training programs (three cost-effective programs)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Parent training program combining group discussion and video-tape modeling
Number of subjects: 154
Study: 322835

Group type: EXPERIMENTAL
Intervention: Regimen A (cytosine arabinoside and 6-thioguanine administered every 12 hours until marrow cellularity reduced by at least 50%)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Regimen B (cytosine arabinoside and 6-thioguanine administered every 12 hours for 5 days with 5-7 days rest intervals)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both regimens (A and B)
Number of subjects: 147
Study: 30700130

Group type: EXPERIMENTAL
Intervention: AB023
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28295268

Group type: EXPERIMENTAL
Intervention: House-to-house education on cervical cancer and breast cancer prevention
Number of subjects: 1327
Study: 25853744

Group type: EXPERIMENTAL
Intervention: Surgical ablation
Number of subjects: 260

Group type: COMPARATOR
Intervention: Pulmonary-vein isolation
Number of subjects: 260

Group type: COMPARATOR
Intervention: Biatrial maze procedure
Number of subjects: 260

Group type: COMPARATOR
Intervention: No ablation
Number of subjects: 260
Study: 24655865

Group type: EXPERIMENTAL
Intervention: Biologic Inguinal Hernia Matrix (IHM; Cook Medical)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polypropylene (PP) mesh
Number of subjects: 100
Study: 22978733

Group type: EXPERIMENTAL
Intervention: Incision-first (IF) technique
Number of subjects: 180

Group type: COMPARATOR
Intervention: Needle-first (NF) technique
Number of subjects: 180
Study: 19276981

Group type: EXPERIMENTAL
Intervention: Water-based exercises
Number of subjects: 48

Group type: COMPARATOR
Intervention: Land-based exercises
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (water-based and land-based exercises)
Number of subjects: 48
Study: 17434608

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol x kg(‐1) min(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15257184

Group type: EXPERIMENTAL
Intervention: Nt-proBNP
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nt-proANP
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nt-proBNP above median value (21.8 pmol/ml)
Number of subjects: 183
Study: 11440917

Group type: EXPERIMENTAL
Intervention: PCOS women (n = 12)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PCOS women (n = 14)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control women (n = 8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control women (n = 12)
Number of subjects: 12
Study: 9814456

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in primary symptomatic HPT (n = 52)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in HPT associated with hemodialysis (n = 19)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in HPT associated with renal transplant (n = 15)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conservative management in primary asymptomatic HPT (n = 21)
Number of subjects: 128
Study: 8032581

Group type: EXPERIMENTAL
Intervention: Dipyrone 2.5 g
Number of subjects: 260

Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 2507481

Group type: EXPERIMENTAL
Intervention: Oral nutrition (normal diet followed by supplemental liquid formula diet)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Enteral nutrition via PEG (percutaneous endoscopically controlled gastrostomy)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Quality of life index measurement
Number of subjects: 99

Group type: COMPARATOR
Intervention: Objective parameters of nutrition
Number of subjects: 99

Group type: COMPARATOR
Intervention: Subjective condition post-DXRT
Number of subjects: 99
Study: 31557056

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 4614
Study: 28759317

Group type: EXPERIMENTAL
Intervention: First-person point of view
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Positive role model
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: First-person point of view with positive role model
Number of subjects: 489

Group type: COMPARATOR
Intervention: Protagonist-reader demographic similarity
Number of subjects: 489
Study: 26447745

Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-preferred music
Number of subjects: 35

Group type: COMPARATOR
Intervention: No music
Number of subjects: 35
Study: 24621836

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21507262

Group type: EXPERIMENTAL
Intervention: Induction of labour (via prostaglandins, Foley catheter or oxytocin)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Expectant management (spontaneous delivery)
Number of subjects: 1760
Study: 17920202

Group type: EXPERIMENTAL
Intervention: Amnion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Topical antimicrobials
Number of subjects: 102
Study: 16502422

Group type: EXPERIMENTAL
Intervention: LIM MUCS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MPS MUCS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: D4S MUCS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall MUCSs
Number of subjects: 28
Study: 14689459

Group type: EXPERIMENTAL
Intervention: Multisensory intervention (auditory, tactile, visual stimulation) for 15 min, twice a day, 5 days a week, for 4 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (routine orphanage care only)
Number of subjects: 58
Study: 11122889

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensification of postremission therapy (multiple courses of high-dose chemotherapy and/or myeloablative therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3+7 chemotherapy regimen (3 days of anthracyclines and 7 days of cytarabine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-tailored therapy
Number of subjects: 0
Study: 9078595

Group type: EXPERIMENTAL
Intervention: Topical ketanserin (n = 69)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal saline (placebo) (n = 71)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical ketanserin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 140
Study: 8002148

Group type: EXPERIMENTAL
Intervention: Whitfield's cream
Number of subjects: 153

Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 153
Study: 3240634

Group type: EXPERIMENTAL
Intervention: Nine-week program of submaximal aerobic exercise three times weekly
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 55
Study: 31621251

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints (C1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture based on zangfu differentiation (C2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints and based on zangfu differentiation (C3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Catheter balloon dilation combined with acupuncture (D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Catheter balloon dilation (B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine treatment (A)
Number of subjects: 90
Study: 28192781

Group type: EXPERIMENTAL
Intervention: Receptive live music
Number of subjects: 70

Group type: COMPARATOR
Intervention: Verbal relaxation exercise
Number of subjects: 70
Study: 25209975

Group type: EXPERIMENTAL
Intervention: Dyadic psychosocial intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 39
Study: 23305349

Group type: EXPERIMENTAL
Intervention: Pneumatic compression boots with 40 mmHg at the heels and 30 mmHg for the legs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no compression)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compression group
Number of subjects: 20
Study: 21512498

Group type: EXPERIMENTAL
Intervention: Neyromidin (15 mg intramuscularly 1 time a day for 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cerebrolysin (10 ml intravenously 1 time a day for 10 days)
Number of subjects: 50
Study: 18312058

Group type: EXPERIMENTAL
Intervention: Quetiapine (600 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 16162678

Group type: EXPERIMENTAL
Intervention: 13C‐UBT 25 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 13C‐UBT 15 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 13C‐UBT 10 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 13C‐UBT 15 mg (post-treatment)
Number of subjects: 300
Study: 12783624

Group type: EXPERIMENTAL
Intervention: Solution-focused follow-up
Number of subjects: 228

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 228
Study: 10865273

Group type: EXPERIMENTAL
Intervention: SPF 30 broad-spectrum sunscreen applied to exposed sites when the child was expected to be in the sun for 30 minutes or more (n=222)
Number of subjects: 309

Group type: COMPARATOR
Intervention: No sunscreen and no advice about sunscreen use (Control group, n=236)
Number of subjects: 309
Study: 9355903

Group type: EXPERIMENTAL
Intervention: Bidisomide 200 mg BID
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Bidisomide 400 mg BID
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Bidisomide 600 mg BID
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Bidisomide (higher doses)
Number of subjects: 1414
Study: 8473088

Group type: EXPERIMENTAL
Intervention: IVIG plus antibiotic prophylaxis (cefoxitin: 2 g one hour prior to, followed by 2 g at the end of operation plus 2 g every six hours for 24 hours)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: IVIG alone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis (cefoxitin)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control (no IVIG)
Number of subjects: 159
Study: 2894980

Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg twice daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg twice daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Matched placebo twice daily
Number of subjects: 128
Study: 29747611

Group type: EXPERIMENTAL
Intervention: Simulated surgical crown lengthening with 1.0 mm buccal ferrule (Group CL/F1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simulated surgical crown lengthening with 2.0 mm buccal ferrule (Group CL/F2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simulated orthodontic forced eruption with 1.0 mm buccal ferrule (Group OE/F1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simulated orthodontic forced eruption with 2.0 mm buccal ferrule (Group OE/F2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with incomplete ferrule preparation (Group F0)
Number of subjects: 40
Study: 27739166

Group type: EXPERIMENTAL
Intervention: FACES instrument
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study: 26320403

Group type: EXPERIMENTAL
Intervention: Birth weight increase (1 kg)
Number of subjects: 4428

Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 4428
Study: 23855171

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 60
Study: 20467146

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy device with defibrillator (CRT-D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable cardiac defibrillator (ICD) device
Number of subjects: 0
Study: 18026864

Group type: EXPERIMENTAL
Intervention: Exercise Telemetry Monitors (ETM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No Exercise Telemetry Monitors (NETM)
Number of subjects: 51
Study: 16177521

Group type: EXPERIMENTAL
Intervention: EEG analysis using detrended fluctuation analysis (DFA)
Number of subjects: 0
Study: 12842671

Group type: EXPERIMENTAL
Intervention: Cataract extraction in patients with pseudoexfoliation syndrome (PEX)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Cataract extraction in patients without pseudoexfoliation syndrome (non-PEX)
Number of subjects: 724
Study: 10388462

Group type: EXPERIMENTAL
Intervention: Telo Cypro (pure copper wire sheet used as bedsheet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8694041

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone, beta 2‐adrenergic receptor agonist, and an oral corticosteroid taper
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous aminophylline and inhaled beta 2‐adrenergic receptor agonist
Number of subjects: 84

Group type: COMPARATOR
Intervention: Beta 2‐adrenergic receptor agonist and corticosteroid taper
Number of subjects: 84
Study: 1676753

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, prednisone, and plasma exchanges (Group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Prednisone and plasma exchanges (Group A)
Number of subjects: 71
Study: 6338693

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 8 g/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 16 g/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 32 g/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE)
Number of subjects: 91
Study: 31958518

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right orbitofrontal cortex (rOFC) for 20 minutes
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 92
Study: 30762895

Group type: EXPERIMENTAL
Intervention: Lusutrombopag 3 mg once daily for ≤ 7 days before an invasive procedure
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Number of subjects: 215
Study: 28449229

Group type: EXPERIMENTAL
Intervention: More, larger and harder pieces of food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less, smaller and softer pieces of food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (more larger harder pieces and less smaller softer pieces)
Number of subjects: 0
Study: 27141168

Group type: EXPERIMENTAL
Intervention: Hard splint
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Soft splint
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Liquid oral splint
Number of subjects: 45
Study: 24241606

Group type: EXPERIMENTAL
Intervention: Home exercise programme (EG, n=53)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal care (CG, n=55)
Number of subjects: 108
Study: 21900844

Group type: EXPERIMENTAL
Intervention: Simplified derived equation for predicting maximal HR: 119 + 0.5 (resting HR) - 0.5 (age) - (0, if test was completed using a treadmill; 5, if using a stationary bike)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equation 220 - age
Number of subjects: 0
Study: 21034901

Group type: EXPERIMENTAL
Intervention: AFI+TH (autofluorescence imaging with a transparent hood)
Number of subjects: 561

Group type: COMPARATOR
Intervention: WLI alone (white light imaging without a transparent hood)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: WLI+TH (white light imaging with a transparent hood)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: AFI alone (autofluorescence imaging without a transparent hood)
Number of subjects: 561
Study: 17534958

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ER)
Number of subjects: 20
Study: 15875066

Group type: EXPERIMENTAL
Intervention: IL-9
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IL-9R
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hCLCA1 (protein and mRNA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mucin production (periodic acid-Schiff staining)
Number of subjects: 6
Study: 11956848

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (CyA)
Number of subjects: 196
Study: 9708659

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 521
Study: 7543597

Group type: EXPERIMENTAL
Intervention: Self-administration of the AUA symptom index
Number of subjects: 124

Group type: COMPARATOR
Intervention: Interviewer administration of the AUA symptom index
Number of subjects: 124
Study: 2670034

Group type: EXPERIMENTAL
Intervention: iopamidol (200 mgI/ml)
Number of subjects: 261

Group type: COMPARATOR
Intervention: iohexol (240 mgI/ml)
Number of subjects: 261
Study: 315162

Group type: EXPERIMENTAL
Intervention: Coronary arterial bypass surgery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 102
Study: 31924513

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4805

Group type: EXPERIMENTAL
Intervention: Pertuzumab with taxane
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo with taxane
Number of subjects: 4805
Study: 30664453

Group type: EXPERIMENTAL
Intervention: NoteAid (active resource providing definitions for medical concepts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MedlinePlus (passive self-service educational resource)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline group (no resources provided)
Number of subjects: 0
Study: 27755017

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25315667

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil (Med‐EVOO)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (Med‐nuts)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 200
Study: 23579344

Group type: EXPERIMENTAL
Intervention: Fixed-combination brinzolamide, 1%, and brimonidine, 0.2%
Number of subjects: 660

Group type: COMPARATOR
Intervention: Brinzolamide, 1%
Number of subjects: 660

Group type: COMPARATOR
Intervention: Brimonidine, 0.2%
Number of subjects: 660
Study: 20522466

Group type: EXPERIMENTAL
Intervention: Peer-mentoring by a lay-worker fortnightly during pregnancy and monthly for the following year, tailored to participants' wishes (home visits/telephone contacts), additional to usual care.
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Peer-mentoring by a lay-worker
Number of subjects: 343
Study: 19365055

Group type: EXPERIMENTAL
Intervention: Immune globulin IV, 10% caprylate/chromatography purified (IGIV-C)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17533747

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus CMNa (group-A)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Radiotherapy alone (group-B)
Number of subjects: 211